Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

Manipal Health Enterprises / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/manipal-health-enterprises-limited" target="_blank" data-smartkarma-citation="entities:57525:1" rel="noopener">Manipal Health Enterprises (MANIPALH IN)</a> has redeemed the outstanding NCDs worth of INR53B, using the IPO proceeds. The debt reduction is expected to support the company's focus on profitable growth.</li>
<li>Manipal Health has other strong margin drivers. The integration of Sahyadri Hospitals, increasing contribution of high-acuity specialties, and ramping-up of greenfield expansions are key margin drivers.</li>
<li>With long-term structural factors supporting growth of the Indian healthcare delivery market, as a large player with Pan-India presence, Manipal Health is well-positioned to leverage on the growth opportunity.  </li>
</ul>



Manipal Health Enterprises (MANIPALH IN) has redeemed the outstanding NCDs worth of INR53B, using the IPO proceeds. The debt reduction is expected to support the company's focus on profitable growth.
Manipal Health has other strong margin drivers. The integration of Sahyadri Hospitals, increasing contribution of high-acuity specialties, and ramping-up of greenfield expansions are key margin drivers.
With long-term structural factors supporting growth of the Indian healthcare delivery market, as a large player with Pan-India presence, Manipal Health is well-positioned to leverage on the growth opportunity.  


Manipal Health Enterprises (MANIPALH IN): Debt Repayment Done; What Are Next Margin Levers

Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Event-Driven

HealthCare Global Enterprises / Event-Driven

<ul>
<li>The Supreme Court has questioned medicine markups and sought government consideration of wider margin restrictions; a universal 16% cap is not yet established.</li>
<li>Earnings exposure depends on drug billing, procurement economics, and contract terms, while restrictions on captive pharmacy purchases could create a separate volume risk.</li>
<li>Investors should distinguish recoverable earnings pressure from weaker pricing power, then assess whether expansion returns justify existing valuation assumptions.</li>
</ul>


The Supreme Court has questioned medicine markups and sought government consideration of wider margin restrictions; a universal 16% cap is not yet established.
Earnings exposure depends on drug billing, procurement economics, and contract terms, while restrictions on captive pharmacy purchases could create a separate volume risk.
Investors should distinguish recoverable earnings pressure from weaker pricing power, then assess whether expansion returns justify existing valuation assumptions.


Supreme Court Drug-Pricing Scrutiny in India: Which Hospital Earnings Are Actually Exposed?

<ul>
<li>
<a href="https://www.smartkarma.com/entities/ihh-healthcare-bhd" target="_blank" data-smartkarma-citation="entities:876:1" rel="noopener">IHH Healthcare (IHH MK)</a> is facing a legal headwind after a Tokyo District Court dismissed its damage claims against Daiichi Sankyo related to the acquisition of Fortis Healthcare.</li>
<li>However, accelerated growth momentum reported in 2Q26 financial result, in particular recovery in Singapore operation, raises conviction on the strength of the core operation of IHH.</li>
<li>Amid rising demand, IHH remains confident in its growth path. The company has reaffirmed 2026 EBITDA and PATMI margins guidance at 22–24% and 8–10%, respectively.</li>
</ul>



IHH Healthcare (IHH MK) is facing a legal headwind after a Tokyo District Court dismissed its damage claims against Daiichi Sankyo related to the acquisition of Fortis Healthcare.
However, accelerated growth momentum reported in 2Q26 financial result, in particular recovery in Singapore operation, raises conviction on the strength of the core operation of IHH.
Amid rising demand, IHH remains confident in its growth path. The company has reaffirmed 2026 EBITDA and PATMI margins guidance at 22–24% and 8–10%, respectively.


IHH Healthcare (IHH MK): Faster Growth Momentum in 2Q Raises Hope Amid Persisting Legal Headwinds

Thematic (Sector/Industry)

<ul>
<li>Celltrion inlicensed two antibody-based new drug candidates for the treatment of autoimmune diseases in KRW1T deal. Dong-A ST received approval for epilepsy drug, Xcopri, developed by SK Biopharmaceuticals in Korea.</li>
<li>Hanmi Pharmaceutical will distribute and sell three major COPD treatments developed by Boehringer Ingelheim. Shandong Boan Biotechnology’s marketing application for denosumab biosimilar has been accepted in the UK.  </li>
<li>Eisai has settled patent infringement litigation with Torrent Pharmaceuticals related to Lenvima in the U.S. Otsuka Holdings initiated Phase 3 clinical trial evaluating quabodepistat, for the treatment of multidrug-resistant tuberculosis.</li>
</ul>


Celltrion inlicensed two antibody-based new drug candidates for the treatment of autoimmune diseases in KRW1T deal. Dong-A ST received approval for epilepsy drug, Xcopri, developed by SK Biopharmaceuticals in Korea.
Hanmi Pharmaceutical will distribute and sell three major COPD treatments developed by Boehringer Ingelheim. Shandong Boan Biotechnology’s marketing application for denosumab biosimilar has been accepted in the UK.  
Eisai has settled patent infringement litigation with Torrent Pharmaceuticals related to Lenvima in the U.S. Otsuka Holdings initiated Phase 3 clinical trial evaluating quabodepistat, for the treatment of multidrug-resistant tuberculosis.


APAC Healthcare Weekly (November 9) – Celltrion, Dong-A ST, Hanmi Pharm, Boan Bio, Eisai, Otsuka

<ul>
<li>Daiichi Sankyo’s indication expansion application for Enhertu has been accepted for review by FDA for certain types of breast cancers. Santen’s new drug application has been accepted in China.  </li>
<li>Hanmi Pharm entered into a global licensing agreement with Gilead Sciences granting Gilead the exclusive rights to develop and commercialize encequidar. Boryung is acquiring Sanofi’s cytotoxic anti-cancer drug Taxotere.</li>
<li>IHH Healthcare received SEBI approval for mandatory open offer for 26% stake in Fortis Healthcare. Lupin has launched Liraglutide prefilled pen, bioequivalent to Victoza, in the U.S.</li>
</ul>


Daiichi Sankyo’s indication expansion application for Enhertu has been accepted for review by FDA for certain types of breast cancers. Santen’s new drug application has been accepted in China.  
Hanmi Pharm entered into a global licensing agreement with Gilead Sciences granting Gilead the exclusive rights to develop and commercialize encequidar. Boryung is acquiring Sanofi’s cytotoxic anti-cancer drug Taxotere.
IHH Healthcare received SEBI approval for mandatory open offer for 26% stake in Fortis Healthcare. Lupin has launched Liraglutide prefilled pen, bioequivalent to Victoza, in the U.S.


APAC Healthcare Weekly (October 5) – Daiichi Sankyo, Santen, Hanmi Pharm, Boryung, IHH Health, Lupin

India

Fortis Healthcare Ltd. is a health care provider.  The Company operates multi- specialty hospitals, a boutique-style hospital, and various satellite and heart command centers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Fortis Healthcare (FORH IN)

Manipal Health Enterprises (MANIPALH IN): Debt Repayment Done; What Are Next Margin Levers

Manipal redeemed outstanding NCDs worth of INR53B, using IPO proceeds. Debt reduction should support profitable growth. Integration of Sahyadri...

Tina Banerjee

Supreme Court Drug-Pricing Scrutiny in India: Which Hospital Earnings Are Actually Exposed?

As the Supreme Court targets hospital drug markups, which earnings are actually exposed? Read our breakdown of true margin risks beyond headline...

Nimish Maheshwari

IHH Healthcare (IHH MK): Faster Growth Momentum in 2Q Raises Hope Amid Persisting Legal Headwinds

IHH is facing a legal headwind after a Tokyo Court dismissed its damage claims against Daiichi Sankyo. However, accelerated momentum reported in...

Tina Banerjee

APAC Healthcare Weekly (November 9) – Celltrion, Dong-A ST, Hanmi Pharm, Boan Bio, Eisai, Otsuka

Celltrion inlicensed two antibody drug candidates in KRW1T deal. Dong-A got domestic approval for Xcopri. Hanmi Pharm will distribute Boehringer...

Tina Banerjee

APAC Healthcare Weekly (October 5) – Daiichi Sankyo, Santen, Hanmi Pharm, Boryung, IHH Health, Lupin

Daiichi Sankyo’s label expansion application for Enhertu has been accepted by FDA. Hanmi Pharm entered into global licensing agreement with Gilead...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)